Image
Recommendation
Management of the axilla – Indications for further axillary treatment #3
Do not offer further axillary treatment after breast-conserving surgery and breast radiation therapy or mastectomy to patients who have only micrometastases (0.2 - ≤2 mm) in their sentinel lymph nodes, or who have only isolated tumour cells (0.2 mm) in their sentinel lymph nodes.
Do not offer further axillary treatment after primary surgery to people with invasive breast cancer who have only micrometastases in their sentinel lymph nodes
Do not offer further axillary treatment after primary surgery to people with invasive breast cancer who have only isolated tumour cells in their sentinel lymph nodes. Regard these people as having lymph node negative breast cancer
How this guidance was developed
This recommendation was adapted from the NICE 2018 guidelines (UK). Two source recommendations based on a systematic review of the evidence conducted to September 2017 and which used wording ('Do not offer') indicative of a strong recommendation (using SIGN methods) by the source guideline authors were merged. The source recommendation was adapted by replacing the word ‘people’ with ‘patients’ and by including ‘0.2 - ≤2 mm’ after the word ‘micrometastases’ to add further specificity to this recommendation.
Management of the axilla – Indications for further axillary treatment #3
Recommendation
Do not offer further axillary treatment after breast-conserving surgery and breast radiation therapy or mastectomy to patients who have only micrometastases (0.2 - ≤2 mm) in their sentinel lymph nodes, or who have only isolated tumour cells (0.2 mm) in their sentinel lymph nodes.
Principles in action
Safe and quality care
This recommendation was adapted from the NICE 2018 guidelines (UK). Two source recommendations based on a systematic review of the evidence conducted to September 2017 and which used wording ('Do not offer') indicative of a strong recommendation (using SIGN methods) by the source guideline authors were merged. The source recommendation was adapted by replacing the word ‘people’ with ‘patients’ and by including ‘0.2 - ≤2 mm’ after the word ‘micrometastases’ to add further specificity to this recommendation.